Thomas A. Gardner

5.3k total citations
159 papers, 3.7k citations indexed

About

Thomas A. Gardner is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Surgery. According to data from OpenAlex, Thomas A. Gardner has authored 159 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Pulmonary and Respiratory Medicine, 49 papers in Molecular Biology and 45 papers in Surgery. Recurrent topics in Thomas A. Gardner's work include Virus-based gene therapy research (35 papers), Prostate Cancer Treatment and Research (35 papers) and Renal cell carcinoma treatment (22 papers). Thomas A. Gardner is often cited by papers focused on Virus-based gene therapy research (35 papers), Prostate Cancer Treatment and Research (35 papers) and Renal cell carcinoma treatment (22 papers). Thomas A. Gardner collaborates with scholars based in United States, Japan and Canada. Thomas A. Gardner's co-authors include Chinghai Kao, Michael O. Koch, Liang Cheng, Leland W.K. Chung, Richard Bihrle, Meei‐Huey Jeng, Richard S. Foster, John N. Eble, Noah M. Hahn and Haiyen E. Zhau and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Molecular Biology and Cancer.

In The Last Decade

Thomas A. Gardner

156 papers receiving 3.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas A. Gardner United States 33 1.4k 1.3k 825 814 802 159 3.7k
E. Brian Butler United States 35 792 0.6× 2.1k 1.6× 973 1.2× 433 0.5× 1.2k 1.5× 227 4.7k
Nam Hoon Cho South Korea 38 1.8k 1.3× 1.2k 1.0× 1.0k 1.2× 233 0.3× 1.3k 1.6× 223 4.9k
Donna J. Lager United States 39 1.5k 1.1× 1.3k 1.0× 1.3k 1.6× 577 0.7× 780 1.0× 87 4.9k
Charles Zaloudek United States 41 1.2k 0.9× 1.6k 1.3× 703 0.9× 527 0.6× 616 0.8× 83 5.4k
Toyonori Tsuzuki Japan 40 1.1k 0.8× 2.6k 2.0× 1.6k 1.9× 270 0.3× 1.4k 1.7× 288 5.9k
Matthias D. Hofer United States 33 1.4k 1.0× 1.6k 1.2× 793 1.0× 284 0.3× 549 0.7× 121 3.9k
Masahiro Yao Japan 43 2.9k 2.2× 2.9k 2.3× 987 1.2× 461 0.6× 1.1k 1.3× 269 5.8k
Kyung Chul Moon South Korea 32 1.2k 0.9× 1.5k 1.1× 848 1.0× 175 0.2× 630 0.8× 228 3.9k
Massimo Freschi Italy 43 737 0.5× 3.7k 2.9× 1.6k 2.0× 298 0.4× 1.1k 1.4× 170 6.2k
Hiro‐omi Kanayama Japan 35 1.9k 1.4× 1.4k 1.1× 967 1.2× 237 0.3× 1.0k 1.3× 195 4.0k

Countries citing papers authored by Thomas A. Gardner

Since Specialization
Citations

This map shows the geographic impact of Thomas A. Gardner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas A. Gardner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas A. Gardner more than expected).

Fields of papers citing papers by Thomas A. Gardner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas A. Gardner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas A. Gardner. The network helps show where Thomas A. Gardner may publish in the future.

Co-authorship network of co-authors of Thomas A. Gardner

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas A. Gardner. A scholar is included among the top collaborators of Thomas A. Gardner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas A. Gardner. Thomas A. Gardner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Siegel, Amanda P., Shengzhi Liu, Sunil S. Tholpady, et al.. (2023). Canine-Inspired Chemometric Analysis of Volatile Organic Compounds in Urine Headspace to Distinguish Prostate Cancer in Mice and Men. Cancers. 15(4). 1352–1352. 10 indexed citations
2.
GuhaThakurta, Debraj, Nadeem A. Sheikh, Li-Qun Fan, et al.. (2015). Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome. Clinical Cancer Research. 21(16). 3619–3630. 101 indexed citations
3.
Small, Eric J., Raymond S. Lance, Thomas A. Gardner, et al.. (2015). A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 21(17). 3862–3869. 61 indexed citations
4.
McNeel, Douglas G., Thomas A. Gardner, Celestia S. Higano, et al.. (2014). A Transient Increase in Eosinophils Is Associated with Prolonged Survival in Men with Metastatic Castration-Resistant Prostate Cancer Who Receive Sipuleucel-T. Cancer Immunology Research. 2(10). 988–999. 44 indexed citations
5.
Liu, Nick, Michael Risk, Virgilio George, Bruce W. Robb, & Thomas A. Gardner. (2012). Incisionless Dual Diversions: Creation of Urostomy and Colostomy Using the Da Vinci Robot. Videourology. 26(4). 2 indexed citations
6.
Gardner, Thomas A., Temel Tirkes, Matthew J. Mellon, & Michael O. Koch. (2011). Imaging Techniques for the Patient With Renal Cell Carcinoma. Seminars in Nephrology. 31(3). 245–253. 6 indexed citations
7.
Gardner, Thomas A., et al.. (2010). Robotic Assisted Laparoscopic Re-Do Vesicovaginal Fistula Repair. Neurourology and Urodynamics.
8.
Jiménez, Javier, YP Zhang, Kunho Bae, et al.. (2009). Antitumor activity of Ad-IU2, a prostate-specific replication-competent adenovirus encoding the apoptosis inducer, TRAIL. Cancer Gene Therapy. 17(3). 180–191. 11 indexed citations
9.
Abbosh, Philip H., et al.. (2007). A conditionally replicative, Wnt/β-catenin pathway-based adenovirus therapy for anaplastic thyroid cancer. Cancer Gene Therapy. 14(4). 399–408. 19 indexed citations
10.
Jimènez, Juan A., et al.. (2006). Future Innovations in Treating Advanced Prostate Cancer. Urologic Clinics of North America. 33(2). 247–272. 2 indexed citations
11.
12.
Gardner, Thomas A. & Michael O. Koch. (2005). Prostate Cancer Therapy with High-Intensity Focused Ultrasound. Clinical Genitourinary Cancer. 4(3). 187–192. 18 indexed citations
13.
Koch, Michael O. & Thomas A. Gardner. (2005). Thermal-based treatment options for localized prostate cancer. Current Treatment Options in Oncology. 6(5). 379–387. 5 indexed citations
14.
Lim, Ho Yeong, Miwon Ahn, Hyun Cheol Chung, et al.. (2004). Tumor-specific gene therapy for uterine cervical cancer using MN/CA9-directed replication-competent adenovirus. Cancer Gene Therapy. 11(8). 532–538. 12 indexed citations
15.
Lee, Sang Jin, Xiumei Yang, Chaeyong Jung, et al.. (2003). NFATc1 with AP-3 Site Binding Specificity Mediates Gene Expression of Prostate-specific-membrane-antigen. Journal of Molecular Biology. 330(4). 749–760. 28 indexed citations
16.
17.
Zhang, Shaobo, Jian Gu, Ning‐Sun Yang, et al.. (2002). Relative promoter strengths in four human prostate cancer cell lines evaluated by particle bombardment‐mediated gene transfer*. The Prostate. 51(4). 286–292. 8 indexed citations
18.
Shirakawa, Toshiro, Akinobu Gotoh, Yoshitaka Wada, et al.. (2000). Tissue-Specific Promoters in Gene Therapy for the Treatment of Prostate Cancer. PubMed. 4(2). 73–82. 20 indexed citations
19.
Shirakawa, Toshiro, Thomas A. Gardner, Chinghai Kao, et al.. (2000). p53 Adenoviral vector (Ad-CMV-p53) induced prostatic growth inhibition of primary cultures of human prostate and an experimental rat model. The Journal of Gene Medicine. 2(6). 426–432. 6 indexed citations
20.
Slamovits, Thomas L. & Thomas A. Gardner. (1989). Neuroimaging Neuro-Ophthalmology. Ophthalmology. 96(4). 555–568. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by E. Brian Butler Breakdown of academic impact, for papers by Nam Hoon Cho Breakdown of academic impact, for papers by Donna J. Lager Breakdown of academic impact, for papers by Charles Zaloudek Breakdown of academic impact, for papers by Toyonori Tsuzuki Breakdown of academic impact, for papers by Matthias D. Hofer Breakdown of academic impact, for papers by Masahiro Yao Breakdown of academic impact, for papers by Kyung Chul Moon Breakdown of academic impact, for papers by Massimo Freschi Breakdown of academic impact, for papers by Hiro‐omi Kanayama
Rankless by CCL
2026